The research suggests that breast tumors with low and intermediate estrogen receptor (ER) expression exhibit immune characteristics similar to triple-negative breast cancer (TNBC). The study found comparable levels of immune factors and gene signatures in tumors with ER expression between 1%-50% and those with no ER expression. This challenges the current treatment guidelines and opens up the possibility of immune checkpoint inhibitor therapy for ER+ breast tumors.
เป็นภาษาอื่น
จากเนื้อหาต้นฉบับ
www.medscape.com
ข้อมูลเชิงลึกที่สำคัญจาก
by Megan Brooks ที่ www.medscape.com 06-01-2023
https://www.medscape.com/viewarticle/992641สอบถามเพิ่มเติม